- Home
- GNSS vs CNTB Comparison
GNSS vs CNTB Comparison
Compare GNSS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- CNTB
- Stock Information
- Founded
- GNSS 1992
- CNTB 2012
- Country
- GNSS United States
- CNTB United States
- Employees
- GNSS N/A
- CNTB N/A
- Industry
- GNSS Consumer Electronics/Appliances
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- GNSS Consumer Staples
- CNTB Health Care
- Exchange
- GNSS Nasdaq
- CNTB Nasdaq
- Market Cap
- GNSS 98.9M
- CNTB 44.2M
- IPO Year
- GNSS N/A
- CNTB 2021
- Fundamental
- Price
- GNSS $1.77
- CNTB N/A
- Analyst Decision
- GNSS Strong Buy
- CNTB Strong Buy
- Analyst Count
- GNSS 3
- CNTB 2
- Target Price
- GNSS $5.33
- CNTB $7.50
- AVG Volume (30 Days)
- GNSS 117.0K
- CNTB 103.1K
- Earning Date
- GNSS 08-05-2025
- CNTB 05-15-2025
- Dividend Yield
- GNSS N/A
- CNTB N/A
- EPS Growth
- GNSS N/A
- CNTB N/A
- EPS
- GNSS N/A
- CNTB N/A
- Revenue
- GNSS $27,780,000.00
- CNTB $26,033,000.00
- Revenue This Year
- GNSS $91.14
- CNTB N/A
- Revenue Next Year
- GNSS $75.44
- CNTB N/A
- P/E Ratio
- GNSS N/A
- CNTB N/A
- Revenue Growth
- GNSS N/A
- CNTB N/A
- 52 Week Low
- GNSS $1.46
- CNTB $0.51
- 52 Week High
- GNSS $4.04
- CNTB $1.60
- Technical
- Relative Strength Index (RSI)
- GNSS 57.13
- CNTB 72.64
- Support Level
- GNSS $1.48
- CNTB $1.02
- Resistance Level
- GNSS $1.85
- CNTB $1.07
- Average True Range (ATR)
- GNSS 0.09
- CNTB 0.09
- MACD
- GNSS 0.04
- CNTB 0.01
- Stochastic Oscillator
- GNSS 79.49
- CNTB 91.19
About GNSS Genasys Inc.
Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.